Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~26 mi. (Bern, Switzerland, +199 more cities)

Universitaetsspital Bern ( Site 0710)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~40 mi. (Lausanne, Switzerland, +144 more cities)

Centre Hospitalier Universitaire Vaudois

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

~40 mi. (Lausanne, Switzerland, +34 more cities)

CHUV (centre hospitalier universitaire vaudois) ( Site 0333)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

immunotherapy, +1 more type

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

~40 mi. (Lausanne, Switzerland, +21 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 4602)

Melanoma

lenvatinib, +2 more drugs

immunotherapy, +1 more type

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

~40 mi. (Lausanne, Switzerland, +27 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602)

Melanoma

lenvatinib, +3 more drugs

immunotherapy, +1 more type

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

~40 mi. (Lausanne, Switzerland, +30 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)

Melanoma

lenvatinib, +4 more drugs

immunotherapy, +2 more types

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

~40 mi. (Lausanne, Switzerland, +24 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602)

Melanoma

MK-4830, +3 more drugs

immunotherapy

A Study of SGN-B6A in Advanced Solid Tumors

~40 mi. (Lausanne, Switzerland, +10 more cities)

University Hospital Lausanne CHUV

HER2 Negative

Bladder Carcinoma, +9 more conditions

SGN-B6A

targeted therapy

CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)

~40 mi. (Lausanne, Switzerland)

CHUV Oncology Department

ER Negative, +2 more biomarkers

Breast Carcinoma

CMP-001, +1 more drug

immunotherapy, +2 more types

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

~77 mi. (Basel, Switzerland, +130 more cities)

Universitaetsspital Basel ( Site 1201)

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

~77 mi. (Basel, Switzerland, +127 more cities)

Universitätsspital Basel /ID# 215892

Acute Myeloid Leukemia

azacitidine, +2 more drugs

chemotherapy

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

~77 mi. (Basel, Switzerland, +96 more cities)

Universitatsspital Basel

Diffuse Large B-Cell Lymphoma, +1 more condition

brentuximab vedotin, +2 more drugs

chemotherapy, +1 more type